Suppr超能文献

诺氟沙星选择性肠道去污对肝硬化动物模型中自发性细菌性腹膜炎、细菌移位及生存的影响

Effect of selective bowel decontamination with norfloxacin on spontaneous bacterial peritonitis, translocation, and survival in an animal model of cirrhosis.

作者信息

Runyon B A, Borzio M, Young S, Squier S U, Guarner C, Runyon M A

机构信息

Department of Medicine, University of Louisville, KY 40292, USA.

出版信息

Hepatology. 1995 Jun;21(6):1719-24.

PMID:7768517
Abstract

Selective bowel decontamination with the orally administered quinolone antibiotic, norfloxacin, has been shown to suppress gut gram-negative bacteria and help prevent gram-negative infections in cirrhotic patients who are at high risk of bacterial infection. Because this drug does not eradicate gram-positive organisms, it is conceivable that gram-positives could replace the suppressed gram-negatives in the gut and lead to subsequent infection. Also the effect of norfloxacin on translocation (as defined by culture positivity of mesenteric lymph nodes) has received little attention. In this study, the effect of oral norfloxacin on translocation, bacterial peritonitis, and survival was investigated in an animal model of carbon tetrachloride-induced cirrhosis and ascites. Treated rats received daily doses of orally administered norfloxacin from the onset of cirrhosis until they died or were killed. Controls received no antibiotic. Norfloxacin led to a reduction in bacterial peritonitis from 70% in untreated cirrhotic controls to 28% in treated cirrhotic rats; these data were statistically significant (P = .012). There was no effect on overall translocation rate (28% with norfloxacin vs. 50% without norfloxacin) (P > .1). Gram-positives were isolated in 100% of the bacterial peritonitis episodes and in 71.4% of culture-positive mesenteric lymph nodes in treated animals compared with only 25% of peritonitis episodes and 10% of culture-positive mesenteric lymph nodes of untreated cirrhotic controls (P < .01 for peritonitis and P < .05 for translocation). The survival rate was not different between groups (P > .1).(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

口服喹诺酮类抗生素诺氟沙星进行选择性肠道去污已被证明可抑制肠道革兰氏阴性菌,并有助于预防有细菌感染高风险的肝硬化患者发生革兰氏阴性菌感染。由于这种药物不能根除革兰氏阳性菌,因此可以想象革兰氏阳性菌可能会取代肠道中被抑制的革兰氏阴性菌并导致随后的感染。此外,诺氟沙星对移位(以肠系膜淋巴结培养阳性定义)的影响很少受到关注。在本研究中,在四氯化碳诱导的肝硬化和腹水动物模型中研究了口服诺氟沙星对移位、细菌性腹膜炎和存活率的影响。从肝硬化开始直至死亡或被处死,治疗组大鼠每日口服诺氟沙星。对照组不使用抗生素。诺氟沙星使细菌性腹膜炎的发生率从未治疗的肝硬化对照组的70%降至治疗的肝硬化大鼠的28%;这些数据具有统计学意义(P = 0.012)。对总体移位率没有影响(诺氟沙星组为28%,无诺氟沙星组为50%)(P > 0.1)。在治疗动物的100%细菌性腹膜炎发作和71.4%培养阳性的肠系膜淋巴结中分离出革兰氏阳性菌,而未治疗的肝硬化对照组仅25%的腹膜炎发作和10%培养阳性的肠系膜淋巴结中分离出革兰氏阳性菌(腹膜炎P < 0.01,移位P < 0.05)。两组之间的存活率没有差异(P > 0.1)。(摘要截短至250字)

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验